These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6283285)

  • 1. Total serum angiotensin converting enzyme activity in rats and dogs after enalapril maleate (MK-421).
    Ulm EH; Vassil TC
    Life Sci; 1982 Apr; 30(14):1225-30. PubMed ID: 6283285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
    Sweet CS
    Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enalapril, a new nonsulfhydryl angiotensin converting enzyme inhibitor, does not potentiate morphine analgesia.
    Mojaverian P; Swanson BN; Ferguson RK
    Eur J Pharmacol; 1984 Feb; 98(2):303-6. PubMed ID: 6325220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of angiotensin-converting enzyme with the ACE inhibitory compound MK-421 in rat lung.
    Forslund T; Fyhrquist F; Grönhagen-Riska C; Tikkanen I
    Eur J Pharmacol; 1982 May; 80(1):121-5. PubMed ID: 6284528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitro.
    Swanson BN; Hichens M; Mojaverian P; Ferguson RK; Vlasses PH; Dudash M
    Res Commun Chem Pathol Pharmacol; 1981 Sep; 33(3):525-36. PubMed ID: 6276950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.
    Jackson B; Cubela R; Johnston CI
    J Hypertens; 1984 Aug; 2(4):371-7. PubMed ID: 6099390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
    Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
    J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physiological disposition and metabolism of enalapril maleate in laboratory animals.
    Tocco DJ; deLuna FA; Duncan AE; Vassil TC; Ulm EH
    Drug Metab Dispos; 1982; 10(1):15-9. PubMed ID: 6124377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of angiotensin converting enzyme inhibitors in serum by radioinhibitor binding displacement assay.
    Jackson B; Cubela R; Johnston CI
    Biochem Pharmacol; 1987 Apr; 36(8):1357-60. PubMed ID: 3036166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of enalapril, a new converting enzyme inhibitor, in hypertension.
    Ferguson RK; Vlasses PH; Swanson BN; Mojaverian P; Hichens M; Irvin JD; Huber PB
    Clin Pharmacol Ther; 1982 Jul; 32(1):48-53. PubMed ID: 6282527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension.
    Jackson B; Johnston CI
    Clin Exp Pharmacol Physiol; 1984; 11(4):355-9. PubMed ID: 6097377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue angiotensin converting enzyme inhibition as an index of the disposition of enalapril (MK-421) and metabolite MK-422.
    Cohen ML; Kurz KD; Schenck KW
    J Pharmacol Exp Ther; 1983 Jul; 226(1):192-6. PubMed ID: 6306224
    [No Abstract]   [Full Text] [Related]  

  • 14. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man.
    Ulm EH
    Drug Metab Rev; 1983; 14(1):99-110. PubMed ID: 6301792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
    Uechi M; Imamoto S; Ishikawa Y
    J Vet Med Sci; 2002 Apr; 64(4):385-7. PubMed ID: 12014588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
    Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W; Muscará MN; Martins AR; Moreno H; Mendes GB; de Nucci G
    Eur J Clin Pharmacol; 1996; 50(5):399-405. PubMed ID: 8839663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme responses following enalapril in the sodium deficient rat.
    Longman SD; Howlett DR
    Eur J Pharmacol; 1986 Apr; 123(3):379-86. PubMed ID: 3013653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A; Boner G; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial.
    Stokes GS; Monaghan JC; Marwood JF; Okoro EO; Johnston H
    Clin Exp Pharmacol Physiol; 1992 May; 19(5):297-9. PubMed ID: 1325880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.